Andreas Bergsten - Mertiva AB CEO and President and Director

DMYDF -- USA Stock  

USD 4.68  0.0024  0.05%

Mr. Andreas Bergsten was Chief Executive Officer of Mertiva AB since April 22, 2013. He has also been Member of the Board of Directors of the Company since February 21, 2014. He is consultant in finance and business management and has, in his capacity as a consultant, primarily worked for VC and private equity firms. In the past, he has served as Chief Financial Officer of four different companies and, prior to this, he was employed at Citigroup, initially as a financial analyst and subsequently as a relationship manager. He is employed as CEO of GForvaltning. He holds a MS degree in Business Administration and Economics from the Stockholm School of Economics and the McGill University MBA Program.
Age: 50  CEO Since 2014  MBA    
46 86 61 00 26

Management Efficiency

The company has return on total asset (ROA) of (0.1) % which means that it has lost $0.1 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of 153.09 % meaning that it generated $153.09 on every $100 dollars invested by stockholders.

Similar Executives

Found 8 records

CEO Since

Larry PageAlphabet
Juan GarzonEcopetrol S A
Satya NadellaMicrosoft Corporation
Luisa LafaurieEcopetrol S A
Sundar PichaiAlphabet
Tim CookApple
Lamberto AndreottiBristol Myers Squibb Company
Timothy CookApple

Entity Summary

Mertiva AB , through its interest in Mercodia AB, develops, manufactures, and distributes ELISA assays in the areas of diabetes, obesity, and cardiovascular diseases. Mertiva AB was founded in 1994 and is based in Stockholm, Sweden. Mertiva AB is traded on OTC Market in USA.Mertiva AB (DMYDF) is traded on OTC Market in USA and employs 7 people.

Mertiva AB Management Team

Andreas Bergsten, CEO and President and Director
Tommy Israelsson, Director
Hakan Blomdahl, Chairman of the Board

Stock Performance Indicators

Current Sentiment - DMYDF

Mertiva AB Investor Sentiment

Macroaxis portfolio users are insensible in their opinion about investing in Mertiva AB. What is your trading attitude regarding investing in Mertiva AB? Are you bullish or bearish?
50% Bullish
50% Bearish

Mertiva AB Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Mertiva AB and Bristol Myers Squibb. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Additionally see Investing Opportunities. Please also try Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of macroaxis ideas.